A wnaiff y Gweinidog gadarnhau a fu unrhyw gynnydd pellach rhwng Vertex Pharmaceuticals, GIG Cymru a Grŵp Strategaeth Feddyginiaethau Cymru ynglŷn â defnyddio'r feddyginiaeth ffibrosis systig Orkambi?
Wedi'i ateb gan Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol | Wedi'i ateb ar 22/01/2019
The All Wales Medicine Strategy Group contacted Vertex Pharmaceuticals again in November 2018 but the company has not submitted Orkambi® for appraisal. It is for the company to offer a specific commercial arrangement for Orkambi® with the NHS in Wales, taking account of the concerns around cost and clinical benefit previously identified by NICE.